Jubilant Life Sciences Q3 net profit at Rs 27 cr due to robust sales
Strong volume growth in generics and speciality pharma continued to drive performance for the segment, it added.
Income from operations in Life Science Ingredients segment during the period stood at Rs 641 crore, showing a growth of 20 per cent YoY with a 49 per cent contribution to overall revenues, Jubilant Life Sciences said.
The company's products and services are available in 90 countries as part of its strategic geographic expansion in key markets across business lines, it added.
Shares of Jubilant Life Sciences were today trading at Rs 220 per scrip in the afternoon trade on BSE, up 2.14 per cent from its previous close.
Be the first to comment.